Physician profile
Edmund J Maclaughlin
NPI 1912966268
$409,646.07
in general payments reported to CMS, 2019-2025
39 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $19K · 2021: $24K · 2022: $24K · 2023: $65K · 2024: $100K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138K · Travel and Lodging: $71K · Honoraria: $45K · Food and Beverage: $9,041 · Consulting Fee: $3,613 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,828.75 |
| Travel and Lodging | $70,552.67 |
| Honoraria | $44,685.00 |
| Food and Beverage | $9,040.64 |
| Consulting Fee | $3,612.50 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $270,881.42 | 2019-2025 | Krystexxa, Evenity, Amjevita |
| Horizon Therapeutics Plc | $79,970.35 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $32,125.05 | 2019-2025 | Taltz, Kisunla |
| Sobi, INC | $16,034.82 | 2020-2025 | |
| Invivyd INC | $2,172.50 | 2025 | Pemgarda |
| Janssen Biotech, INC. | $1,917.91 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,384.46 | 2019-2024 | |
| Ucb, INC. | $807.08 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $493.70 | 2020-2025 | Acthar |
| Pfizer INC. | $489.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $413.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $373.07 | 2019-2021 | |
| Genzyme Corporation | $346.51 | 2019-2025 | |
| Radius Health, INC. | $292.81 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $233.21 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmund Maclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.